515 related articles for article (PubMed ID: 31072576)
1. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
[TBL] [Abstract][Full Text] [Related]
2. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
[TBL] [Abstract][Full Text] [Related]
3. Utilizing human induced pluripotent stem cells to study atrial arrhythmias in the short QT syndrome.
Shiti A; Arbil G; Shaheen N; Huber I; Setter N; Gepstein L
J Mol Cell Cardiol; 2023 Oct; 183():42-53. PubMed ID: 37579942
[TBL] [Abstract][Full Text] [Related]
4. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
[TBL] [Abstract][Full Text] [Related]
5. Optogenetic modulation of cardiac action potential properties may prevent arrhythmogenesis in short and long QT syndromes.
Gruber A; Edri O; Huber I; Arbel G; Gepstein A; Shiti A; Shaheen N; Chorna S; Landesberg M; Gepstein L
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 34100384
[TBL] [Abstract][Full Text] [Related]
6. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.
Luo C; Wang K; Zhang H
PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743
[TBL] [Abstract][Full Text] [Related]
7. Human Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets Expressing Genetically Encoded Voltage Indicator for Pharmacological and Arrhythmia Studies.
Shaheen N; Shiti A; Huber I; Shinnawi R; Arbel G; Gepstein A; Setter N; Goldfracht I; Gruber A; Chorna SV; Gepstein L
Stem Cell Reports; 2018 Jun; 10(6):1879-1894. PubMed ID: 29754959
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the CACNA1C-R518C Missense Mutation in the Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium Channel Perturbation.
Estes SI; Ye D; Zhou W; Dotzler SM; Tester DJ; Bos JM; Kim CSJ; Ackerman MJ
Circ Genom Precis Med; 2019 Aug; 12(8):e002534. PubMed ID: 31430211
[TBL] [Abstract][Full Text] [Related]
9. Large-Scale Simulation of the Phenotypical Variability Induced by Loss-of-Function Long QT Mutations in Human Induced Pluripotent Stem Cell Cardiomyocytes.
Paci M; Casini S; Bellin M; Hyttinen J; Severi S
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428582
[TBL] [Abstract][Full Text] [Related]
10. Overlap Arrhythmia Syndromes Resulting from Multiple Genetic Variations Studied in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Treat JA; Pfeiffer R; Barajas-Martinez H; Goodrow RJ; Bot C; Haedo RJ; Knox R; Cordeiro JM
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281161
[TBL] [Abstract][Full Text] [Related]
11. Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
Lan H; Xu Q; El-Battrawy I; Zhong R; Li X; Lang S; Cyganek L; Borggrefe M; Zhou X; Akin I
Front Pharmacol; 2020; 11():554422. PubMed ID: 33154722
[TBL] [Abstract][Full Text] [Related]
12. Modeling mutation-specific arrhythmogenic phenotypes in isogenic human iPSC-derived cardiac tissues.
Maurissen TL; Kawatou M; López-Dávila V; Minatoya K; Yamashita JK; Woltjen K
Sci Rep; 2024 Jan; 14(1):2586. PubMed ID: 38297132
[TBL] [Abstract][Full Text] [Related]
13. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
14. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
[TBL] [Abstract][Full Text] [Related]
15. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
[TBL] [Abstract][Full Text] [Related]
16. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
Jæger KH; Wall S; Tveito A
PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
[TBL] [Abstract][Full Text] [Related]
17. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
[TBL] [Abstract][Full Text] [Related]
18. Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation.
Wuriyanghai Y; Makiyama T; Sasaki K; Kamakura T; Yamamoto Y; Hayano M; Harita T; Nishiuchi S; Chen J; Kohjitani H; Hirose S; Yokoi F; Gao J; Chonabayashi K; Watanabe K; Ohno S; Yoshida Y; Kimura T; Horie M
Heart Rhythm; 2018 Oct; 15(10):1566-1574. PubMed ID: 29857160
[TBL] [Abstract][Full Text] [Related]
19. Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation.
Yamamoto Y; Makiyama T; Harita T; Sasaki K; Wuriyanghai Y; Hayano M; Nishiuchi S; Kohjitani H; Hirose S; Chen J; Yokoi F; Ishikawa T; Ohno S; Chonabayashi K; Motomura H; Yoshida Y; Horie M; Makita N; Kimura T
Hum Mol Genet; 2017 May; 26(9):1670-1677. PubMed ID: 28335032
[TBL] [Abstract][Full Text] [Related]
20. Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2.
Giannetti F; Barbieri M; Shiti A; Casini S; Sager PT; Das S; Pradhananga S; Srinivasan D; Nimani S; Alerni N; Louradour J; Mura M; Gnecchi M; Brink P; Zehender M; Koren G; Zaza A; Crotti L; Wilde AAM; Schwartz PJ; Remme CA; Gepstein L; Sala L; Odening KE
Europace; 2023 May; 25(5):. PubMed ID: 37099628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
